Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer, Cancer, Kidney Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 19 - 120 |
| Updated: | 4/17/2018 |
| Start Date: | October 2007 |
| End Date: | April 16, 2010 |
Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers that predict response to high-dose
aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.
doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers that predict response to high-dose
aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.
OBJECTIVES:
- Determine the relationship of peripheral blood lymphocyte phenotype pattern in patients
with metastatic renal cell carcinoma or metastatic melanoma to response to high-dose
aldesleukin (IL-2).
- Determine the relationship of peripheral blood mononuclear cells gene microarray
patterns in patients with metastatic renal cell carcinoma or metastatic melanoma to
response to high-dose IL-2.
- Determine the frequency of mutations on genes encoding for IL-2 receptor A and B.
OUTLINE: Patients receive high-dose aldesleukin (IL-2) as part of standard treatment on days
1 and 8. Courses repeat every 3 weeks in the absence of disease progression or unacceptable
toxicity.
Patients undergo blood collection at baseline, prior to beginning course 2, and 4 weeks after
the completion of course 2. Samples are analyzed using peripheral blood cytometry, gene
microarray analysis, and IL-2 receptor single-nucleotide polymorphism techniques.
- Determine the relationship of peripheral blood lymphocyte phenotype pattern in patients
with metastatic renal cell carcinoma or metastatic melanoma to response to high-dose
aldesleukin (IL-2).
- Determine the relationship of peripheral blood mononuclear cells gene microarray
patterns in patients with metastatic renal cell carcinoma or metastatic melanoma to
response to high-dose IL-2.
- Determine the frequency of mutations on genes encoding for IL-2 receptor A and B.
OUTLINE: Patients receive high-dose aldesleukin (IL-2) as part of standard treatment on days
1 and 8. Courses repeat every 3 weeks in the absence of disease progression or unacceptable
toxicity.
Patients undergo blood collection at baseline, prior to beginning course 2, and 4 weeks after
the completion of course 2. Samples are analyzed using peripheral blood cytometry, gene
microarray analysis, and IL-2 receptor single-nucleotide polymorphism techniques.
DISEASE CHARACTERISTICS:
- Diagnosis of metastatic renal cell carcinoma or metastatic melanoma
- Must be receiving treatment with high-dose aldesleukin as part of standard therapy
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
1
site
985950 Nebraska Medical Center
Omaha, Nebraska 68198
Omaha, Nebraska 68198
402-559-4090
UNMC Eppley Cancer Center at the University of Nebraska Medical Center The Fred & Pamela...
Click here to add this to my saved trials
